A Phase III Randomized Trial of Thalidomide Plus Zoledronic Acid Versus Zoledronic Acid Alone in Patients With Early Stage Multiple Myeloma.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Thalidomide (Primary) ; Zoledronic acid (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- 29 Jul 2010 Planned end date changed from 1 Dec 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Apr 2008 Study centres added: Mayo Clinic at Scottsdale, Arizona, and Mayo Clinic at Jacksonville, Florida, USA.